These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit. Qiu H; Liu-Bujalski L; Caldwell RD; Follis AV; Gardberg A; Goutopoulos A; Grenningloh R; Head J; Johnson T; Jones R; Mochalkin I; Morandi F; Neagu C; Sherer B Bioorg Med Chem Lett; 2018 Sep; 28(17):2939-2944. PubMed ID: 30122225 [TBL] [Abstract][Full Text] [Related]
6. Shedding Light on Important Waters for Drug Design: Simulations versus Grid-Based Methods. Bucher D; Stouten P; Triballeau N J Chem Inf Model; 2018 Mar; 58(3):692-699. PubMed ID: 29489352 [TBL] [Abstract][Full Text] [Related]
7. A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation. Lopez-Tapia F; Lou Y; Brotherton-Pleiss C; Kuglstatter A; So SS; Kondru R Bioorg Med Chem Lett; 2019 May; 29(9):1074-1078. PubMed ID: 30857747 [TBL] [Abstract][Full Text] [Related]
8. Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton's Tyrosine Kinase Inhibitor. Lee KW; Lee WH; Han BS; Lee JH; Doo EK; Kim JH Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357562 [No Abstract] [Full Text] [Related]
9. Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series. Liu Q; Batt DG; Chaudhry C; Lippy JS; Pattoli MA; Surti N; Xu S; Carter PH; Burke JR; Tino JA Bioorg Med Chem Lett; 2018 Oct; 28(18):3080-3084. PubMed ID: 30097367 [TBL] [Abstract][Full Text] [Related]
10. 4D-QSAR and MIA-QSAR study on the Bruton's tyrosine kinase (Btk) inhibitors. Ma W; Wang Y; Chu D; Yan H J Mol Graph Model; 2019 Nov; 92():357-362. PubMed ID: 31450065 [TBL] [Abstract][Full Text] [Related]
11. Finding the perfect spot for fluorine: improving potency up to 40-fold during a rational fluorine scan of a Bruton's Tyrosine Kinase (BTK) inhibitor scaffold. Lou Y; Sweeney ZK; Kuglstatter A; Davis D; Goldstein DM; Han X; Hong J; Kocer B; Kondru RK; Litman R; McIntosh J; Sarma K; Suh J; Taygerly J; Owens TD Bioorg Med Chem Lett; 2015 Jan; 25(2):367-71. PubMed ID: 25466710 [TBL] [Abstract][Full Text] [Related]
12. Classification of water molecules in protein binding sites. Barillari C; Taylor J; Viner R; Essex JW J Am Chem Soc; 2007 Mar; 129(9):2577-87. PubMed ID: 17288418 [TBL] [Abstract][Full Text] [Related]
13. QSAR analysis of nicotinamidic compounds and design of potential Bruton's tyrosine kinase (Btk) inhibitors. Santos-Garcia L; Assis LC; Silva DR; Ramalho TC; da Cunha EF J Biomol Struct Dyn; 2016 Jul; 34(7):1421-40. PubMed ID: 26305710 [TBL] [Abstract][Full Text] [Related]
14. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis. Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831 [TBL] [Abstract][Full Text] [Related]
15. Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling. Bender AT; Gardberg A; Pereira A; Johnson T; Wu Y; Grenningloh R; Head J; Morandi F; Haselmayer P; Liu-Bujalski L Mol Pharmacol; 2017 Mar; 91(3):208-219. PubMed ID: 28062735 [TBL] [Abstract][Full Text] [Related]
16. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines. Guo X; Yang D; Fan Z; Zhang N; Zhao B; Huang C; Wang F; Ma R; Meng M; Deng Y Eur J Med Chem; 2019 Sep; 178():767-781. PubMed ID: 31234030 [TBL] [Abstract][Full Text] [Related]
17. Thermodynamic Characterization of Hydration Sites from Integral Equation-Derived Free Energy Densities: Application to Protein Binding Sites and Ligand Series. Güssregen S; Matter H; Hessler G; Lionta E; Heil J; Kast SM J Chem Inf Model; 2017 Jul; 57(7):1652-1666. PubMed ID: 28565907 [TBL] [Abstract][Full Text] [Related]
18. Discovery of Potent Bruton's Tyrosine Kinase Inhibitors Using Ligand Based Modeling. Mera WA; Alzihlif M; Taha MO; Khanfar MA Anticancer Agents Med Chem; 2017; 17(2):265-275. PubMed ID: 27671297 [TBL] [Abstract][Full Text] [Related]
19. Role of Bruton's tyrosine kinase in B cells and malignancies. Pal Singh S; Dammeijer F; Hendriks RW Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639 [TBL] [Abstract][Full Text] [Related]
20. Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors. Xue Y; Song P; Song Z; Wang A; Tong L; Geng M; Ding J; Liu Q; Sun L; Xie H; Zhang A J Med Chem; 2018 May; 61(10):4608-4627. PubMed ID: 29715023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]